Eur Rev Med Pharmacol Sci 2021; 25 (23): 7508-7515

DOI: 10.26355/eurrev_202112_27450

Anti-diabetic effects of Protaetia brevitarsis in pancreatic islets and a murine diabetic model

Y.M. Park, E.-M. Noh, H.Y. Lee, D.Y. Shin, Y.H. Lee, Y.G. Kang, E.-J. Na, J.-H. Kim, H.J. Yang, M.J. Kim, K.S. Kim, J.S. Bae, Y.-R. Lee

INVIVO Co. Ltd., Iksan, Jeonbuk, Korea. jsbae78@wku.ac.kr


OBJECTIVE: In this study, the antidiabetic efficacy of Protaetia brevitarsis in alloxan-treated pancreatic islets and db/db mice was investigated. P. brevitarsis was tested for alloxan-mediated cytotoxicity and nitric oxide production in mice pancreatic islets.

MATERIALS AND METHODS: The anti-diabetic effect of P. brevitarsis was also evaluated in db/db mice after 4 weeks of administration. Biochemical analysis, oral glucose tolerance test (OGTT), and pancreatic histological analysis were performed.

RESULTS: P. brevitarsis displayed hypoglycemic activity in alloxan-treated mice pancreatic islets. Our results showed that P. brevitarsis protects pancreatic islets from cytotoxicity. Moreover, daily oral supplementation with P. brevitarsis for 4 weeks reduced plasma glucose levels without affecting body weight and food intake, elevated glucose tolerance in OGTT, improved blood lipid parameters, inhibited fat accumulation, and restored islet structure of db/db mice.

CONCLUSIONS: The present study provided evidence for the anti‑diabetic effect of P. brevitarsis in alloxan-treated pancreatic islets and db/db mice. These results suggest that P. brevitarsis may be used as an adjunctive anti-diabetic agent or as a functional food.

Free PDF Download

To cite this article

Y.M. Park, E.-M. Noh, H.Y. Lee, D.Y. Shin, Y.H. Lee, Y.G. Kang, E.-J. Na, J.-H. Kim, H.J. Yang, M.J. Kim, K.S. Kim, J.S. Bae, Y.-R. Lee
Anti-diabetic effects of Protaetia brevitarsis in pancreatic islets and a murine diabetic model

Eur Rev Med Pharmacol Sci
Year: 2021
Vol. 25 - N. 23
Pages: 7508-7515
DOI: 10.26355/eurrev_202112_27450